Close Menu

NEW YORK — The US Food and Drug Administration on Tuesday granted Emergency Use Authorization for Babson Diagnostics' SAR-CoV-2 immunoassay.

The test is designed to detect immunoglobulin G antibodies against SARS-CoV-2 in human serum and plasma, and is performed on Siemens Healthineers' Atellica IM Analyzer, according to the FDA. The test may only be performed by the Austin, Texas-based company.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.